NanoBio Corporation and GlaxoSmithKline Commence Phase 3 Studies of Nanoemulsion-based OTC Treatment for Cold Sores
NanoBio® Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare (GSK CH).